CO7160080A2 - Composiciones lipídicas de racecadotrillo - Google Patents

Composiciones lipídicas de racecadotrillo

Info

Publication number
CO7160080A2
CO7160080A2 CO14279647A CO14279647A CO7160080A2 CO 7160080 A2 CO7160080 A2 CO 7160080A2 CO 14279647 A CO14279647 A CO 14279647A CO 14279647 A CO14279647 A CO 14279647A CO 7160080 A2 CO7160080 A2 CO 7160080A2
Authority
CO
Colombia
Prior art keywords
racecadot
lipid compositions
refers
liver
metazolamide
Prior art date
Application number
CO14279647A
Other languages
English (en)
Inventor
Der-Yang Lee
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of CO7160080A2 publication Critical patent/CO7160080A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere generalmente al usode metazolamida en terapia. La descripción se refiere ademásal tratamiento de disfunción hepática, o mejora de la funciónhepática, en un paciente.
CO14279647A 2012-06-28 2014-12-19 Composiciones lipídicas de racecadotrillo CO7160080A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665470P 2012-06-28 2012-06-28
US201361787597P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CO7160080A2 true CO7160080A2 (es) 2015-01-15

Family

ID=48790652

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14279647A CO7160080A2 (es) 2012-06-28 2014-12-19 Composiciones lipídicas de racecadotrillo

Country Status (17)

Country Link
US (1) US10039712B2 (es)
EP (1) EP2866789B1 (es)
JP (1) JP6282645B2 (es)
KR (1) KR20150023876A (es)
CN (1) CN104411299B (es)
AU (1) AU2013282413B2 (es)
BR (1) BR112014032759A2 (es)
CA (1) CA2876929A1 (es)
CO (1) CO7160080A2 (es)
HK (1) HK1208178A1 (es)
IN (1) IN2014DN11003A (es)
MX (1) MX2015000217A (es)
NZ (1) NZ702934A (es)
PH (1) PH12014502858A1 (es)
RU (1) RU2632441C2 (es)
SG (1) SG11201408509PA (es)
WO (1) WO2014005032A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2866789B1 (en) 2012-06-28 2018-08-01 Johnson & Johnson Consumer Inc. Racecadotril lipid compositions
US9801819B2 (en) * 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
MA40859A (fr) * 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril
CN107921017A (zh) * 2015-08-07 2018-04-17 强生消费者公司 使用卡多曲组合物进行治疗的方法
CN105125477A (zh) * 2015-08-19 2015-12-09 黑龙江佰彤儿童药物研究有限公司 一种含消旋卡多曲的药物制剂及制备方法
BR112018013828A2 (pt) * 2016-01-13 2018-12-11 Johnson & Johnson Consumer Inc. composição aprimorada que compreende ao menos uma cadotrila
MA46051A (fr) * 2016-08-23 2021-03-31 Johnson & Johnson Consumer Inc Nouvelle composition améliorée de racecadotril
AU2019225236A1 (en) * 2018-02-26 2020-09-10 R.P. Scherer Technologies, Llc Pharmaceutical dosage form for an emulsion of simethicone and loperamide
CN117660024A (zh) * 2019-07-08 2024-03-08 株式会社Moresco 微型乳剂、用于制造微型乳剂的方法以及微型乳剂的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
FR2623498B1 (fr) 1987-11-24 1990-04-06 Bioprojet Soc Civ Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques
US5136076A (en) 1987-11-24 1992-08-04 Societe Civile Bioprojet Process for the preparation of amino acid-derived enatiomeric compounds
FR2673105B1 (fr) * 1991-02-26 1995-01-13 Bioprojet Soc Civ Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections.
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
US20020028248A1 (en) 1996-03-14 2002-03-07 Takayuki Tsukada Rapid-release microdispersible ecadotril preparation
WO1998040051A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
CA2415957C (en) 2000-06-23 2010-08-10 Bioprojet Dry powder formulation comprising racecadotril
GB0015490D0 (en) 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
EP1563848A1 (en) 2004-02-12 2005-08-17 Bioprojet New combinations of an anti-emetic agent and an enkephalinase inhibitor
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
CN101103960B (zh) 2006-07-14 2010-12-08 海南盛科生命科学研究院 一种含有消旋卡多曲的干混悬剂及其制备方法
CN101264065A (zh) * 2008-04-18 2008-09-17 盐城苏海制药有限公司 消旋卡多曲滴丸及其制备方法
US20100330169A1 (en) 2009-06-29 2010-12-30 Frank Bunick Pharmaceutical Tablet Containing A Liquid Filled Capsule
CN102018707A (zh) 2010-11-29 2011-04-20 昆明邦宇制药有限公司 一种治疗腹泻的药物组合物及其制剂
EP2462922A1 (en) * 2010-12-10 2012-06-13 Bioprojet New form of administration of enkephalinase inhibitor
CN102133186B (zh) * 2011-03-18 2012-08-01 海南美大制药有限公司 一种消旋卡多曲脂质体固体制剂
CN102327234B (zh) 2011-09-28 2017-04-12 海南康芝药业股份有限公司 一种消旋卡多曲干混悬剂
BR112014032801A2 (pt) 2012-06-28 2017-06-27 Mcneil Ppc Inc composições líquidas de racecadotril
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
US9114171B2 (en) 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
EP2866789B1 (en) 2012-06-28 2018-08-01 Johnson & Johnson Consumer Inc. Racecadotril lipid compositions
TR201801726T4 (tr) 2012-12-26 2018-03-21 Ilko Ilac Sanayi Veticaret A S Rasekadotri̇l ve farmasöti̇k bi̇leşi̇mleri̇.
CN107921017A (zh) 2015-08-07 2018-04-17 强生消费者公司 使用卡多曲组合物进行治疗的方法

Also Published As

Publication number Publication date
SG11201408509PA (en) 2015-01-29
AU2013282413B2 (en) 2018-04-19
CA2876929A1 (en) 2014-01-03
PH12014502858A1 (en) 2015-02-23
JP2015522031A (ja) 2015-08-03
US20140005262A1 (en) 2014-01-02
MX2015000217A (es) 2015-04-10
CN104411299A (zh) 2015-03-11
RU2015102597A (ru) 2016-08-20
NZ702934A (en) 2017-02-24
JP6282645B2 (ja) 2018-02-21
BR112014032759A2 (pt) 2017-06-27
US10039712B2 (en) 2018-08-07
EP2866789A1 (en) 2015-05-06
AU2013282413A1 (en) 2015-01-22
RU2632441C2 (ru) 2017-10-04
EP2866789B1 (en) 2018-08-01
KR20150023876A (ko) 2015-03-05
IN2014DN11003A (es) 2015-09-25
WO2014005032A1 (en) 2014-01-03
HK1208178A1 (en) 2016-02-26
CN104411299B (zh) 2017-11-10

Similar Documents

Publication Publication Date Title
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
DOP2014000170A (es) Compuestos de imidazopirrolidinona
EA201400178A1 (ru) Лечение рака молочной железы
AR091837A1 (es) Compuestos para inmunoterapia dirigida
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
BR112015011830A2 (pt) compostos e seus métodos de utilização
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PH12015501088A1 (en) Dimeric compounds
IN2014DN06104A (es)
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
NZ628433A (en) Chitosan-derived compositions
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX368628B (es) Tripeptidos antiinflamatorios.
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
MX362111B (es) Un metodo para mejorar la funcion hepatica.
BR112015023730A2 (pt) uso de sedoeptulose como suplemento nutricional
IN2014KN01772A (es)
MX2013008559A (es) Derivados de leptina.
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης